Patent application number | Description | Published |
20100113776 | PYRAZOLE DERIVATIVE - A novel pyrazole derivative of the following formula having a histamine H3 receptor antagonistic effect: | 05-06-2010 |
20100267687 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 10-21-2010 |
20110065667 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 03-17-2011 |
20110065668 | PHENYLPYRAZOLE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 03-17-2011 |
20120022064 | DIHYDROQUINOLINONE DERIVATIVES - The present invention provides a prophylactic or therapeutic agent for dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, allergic rhinitis or other diseases. | 01-26-2012 |
20130123500 | ETHINYL-PYRAZOLE DERIVATIVE - Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like. | 05-16-2013 |
20130137865 | HETEROARYL-PYRAZOLE DERIVATIVE - A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like. | 05-30-2013 |
20140330010 | PHENYLPYRROLE DERIVATIVE - Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficient hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, and depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds. Specifically, there are provided phenylpyrrole compounds represented by the following formula (I) or pharmaceutically acceptable salts thereof: | 11-06-2014 |
20150045553 | PHENYLTRIAZOLE DERIVATIVE - Provided are novel compounds that are useful in the prevention or treatment of such diseases as dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, epilepsy, central convulsion, obesity, diabetes mellitus, hyperlipidemia, narcolepsy, idiopathic hypersomnia, behaviorally induced insufficient sleep syndrome, sleep apnea syndrome, circadian rhythm disorder, parasomnia, sleep related movement disorder, insomnia, depression, or allergic rhinitis, or pharmaceutically acceptable salts of such compounds. Specifically, there are provided phenyltriazole derivatives represented by the following formula (I) or pharmaceutically acceptable salts thereof: | 02-12-2015 |
Patent application number | Description | Published |
20090149711 | ENDOSCOPE SYSTEM - An endoscope system includes an endoscope with a bending portion installed on a distal side of an insertion portion; a bending drive unit which drives and bends the bending portion electrically; a map information storage unit which stores map information digitized by associating an amount of bending and a corresponding three-dimensional position and direction of a distal end of the insertion portion with each other, with a position near a rear end of the bending portion being designated as a reference position; a position and direction detecting unit which detects the position and direction of the distal end of the insertion portion; and a bending control unit which controls the bending drive unit to orient the distal end of the insertion portion into a target direction using the map information. | 06-11-2009 |
20090291940 | AMINOPYRROLIDINE COMPOUND - Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC | 11-26-2009 |
20100076263 | ENDOSCOPE SYSTEM, IMAGE PICKUP SYSTEM AND IMAGE PROCESSING APPARATUS - An endoscope system includes: an endoscope for picking up an image in a body cavity by an image pickup apparatus provided in a distal end of an insertion portion; a position detecting apparatus for detecting, based on luminal information acquired by the image pickup apparatus, position information used for inserting the distal end of the insertion portion; a recording apparatus for recording, in a time-sequential manner, the position information detected by the position detecting apparatus; a determining apparatus for determining whether or not the detecting operation of the position information performed by the position detecting apparatus satisfies a set condition; and a direction calculating apparatus for, when the determination result shows that the set condition is not satisfied, reading out the position information recorded in the recording apparatus and outputting information on a direction in which the distal end of the insertion portion is to be inserted. | 03-25-2010 |
20100204545 | ENDOSCOPE SYSTEM - An endoscope system of the invention includes: an endoscope including an insertion portion, a distal end portion provided on a distal end side of the insertion portion, and a bending portion which is capable of changing a position and an orientation of the distal end portion; a position detecting section for acquiring position information on a position where the distal end portion is located; a passing target position setting section for setting a passing target position for the distal end portion; a path estimating section for estimating a path through which the distal end portion is to be passed; a bending control target position setting section for setting a bending control target position such that the distal end portion reaches the passing target position along the path; and a bending control information calculating section for calculating an amount of bending and a bending direction of the bending portion. | 08-12-2010 |
20100204547 | ENDOSCOPE BENDING CONTROL APPARATUS AND ENDOSCOPE SYSTEM - An endoscope bending control apparatus includes: an image feature value calculating section for calculating, based on an endoscopic image, an image feature value related to a luminal dark part; a bending control section for performing bending control on a bending portion in either one of a first bending operation mode in which a position of the luminal dark part is set as an insertion target and a distal end of the insertion portion is directed to the position and a second bending operation mode in which the distal end of the insertion portion is directed in a direction of the position of the luminal dark part; an operation mode switching section for switching an operation mode from one bending operation mode to the other according to a first switching condition based on the calculated image feature value; and a switching condition changing section for changing the first switching condition. | 08-12-2010 |
20110236995 | METHOD FOR DETERMINING PROSTATE CANCER - The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)), and benign prostatic hyperplasia is determined in the case of 30% or less. | 09-29-2011 |